cyclic RGD peptideCancer Research Peptides
Cilengitide
A synthetic cyclic RGD pentapeptide that inhibits integrins alphavbeta3 and alphavbeta5. Reached Phase 3 for glioblastoma but failed primary endpoint (CENTRIC trial). Furthest-developed integrin-targeting peptide in oncology.
integrin-inhibitoranti-angiogenicglioblastomaclinical-trials
3D Structure
3D Structure
588.66 Da
82 atoms
Lab Tested
No
Harmful Ingredients
0
Contaminants
None
Tested Purity
--
Batch Consistency
No batch data
Mass Spec Profile
ESI-MS (computed)
Batch Info
Latest Batch—
Total Tests0
Unique Vendors0
Vendor Comparison
No vendor data yet
Analysis Summary
Purity Standard
No purity dataLab Reports
0 reports on file
Summary
A synthetic cyclic RGD pentapeptide that inhibits integrins alphavbeta3 and alphavbeta5. Reached Phase 3 for glioblastoma but failed primary endpoint (CENTRIC trial). Furthest-developed integrin-targe…